ダウンロード数: 98
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
23120541.00288-2019.pdf | 550.21 kB | Adobe PDF | 見る/開く |
完全メタデータレコード
DCフィールド | 値 | 言語 |
---|---|---|
dc.contributor.author | Tanimura, Kazuya | en |
dc.contributor.author | Sato, Susumu | en |
dc.contributor.author | Sato, Atsuyasu | en |
dc.contributor.author | Tanabe, Naoya | en |
dc.contributor.author | Hasegawa, Koichi | en |
dc.contributor.author | Uemasu, Kiyoshi | en |
dc.contributor.author | Hamakawa, Yoko | en |
dc.contributor.author | Hirai, Toyohiro | en |
dc.contributor.author | Muro, Shigeo | en |
dc.contributor.alternative | 谷村, 和哉 | ja |
dc.contributor.alternative | 佐藤, 晋 | ja |
dc.contributor.alternative | 佐藤, 篤靖 | ja |
dc.contributor.alternative | 田辺, 直也 | ja |
dc.contributor.alternative | 長谷川, 浩一 | ja |
dc.contributor.alternative | 上桝, 潔 | ja |
dc.contributor.alternative | 濱川, 瑶子 | ja |
dc.contributor.alternative | 平井, 豊博 | ja |
dc.contributor.alternative | 室, 繁郎 | ja |
dc.date.accessioned | 2020-10-23T00:05:32Z | - |
dc.date.available | 2020-10-23T00:05:32Z | - |
dc.date.issued | 2020-04-01 | - |
dc.identifier.issn | 2312-0541 | - |
dc.identifier.uri | http://hdl.handle.net/2433/255619 | - |
dc.description.abstract | Background: Most exacerbations of chronic obstructive pulmonary disease (COPD) are triggered by respiratory tract infections. Adaptive immunity via antibody production is important in preventing infections. Impaired antibody production is reported to be associated with an increased risk of exacerbations of COPD. In the present study, we elucidated whether reduced free light chains (FLCs), which are excessive amounts of light chains produced during antibody synthesis and can be used to estimate systemic antibody production, may be a promising biomarker to predict the risk of exacerbations of COPD. Methods: We enrolled stable male patients with COPD and prospectively observed them for 2 years. At baseline, serum combined FLC (cFLC; sum of kappa and lambda values) and pulmonary function were evaluated. Exacerbation was defined as a worsening of symptoms requiring treatments with antibiotics, corticosteroids or both. Results: 63 patients with stable COPD were enrolled (72.8±8.1 years, GOLD A/B/C/D=24/28/6/5), and 51 patients completed the 2-year follow-up. Serum cFLC was 31.1 mg·L−1 on average and ranged widely (1.4 to 89.9 mg·L−1). The patients with low cFLC (below the mean−sd, n=6) experienced a significantly shorter time to the first exacerbation of COPD (p<0.0001 by the log-rank test). A multivariate Cox proportional hazard model, including the COPD assessment test score, % predicted forced expiratory volume in 1 s (FEV1 % pred), and number of previous exacerbations demonstrated that low cFLC and low FEV1 % pred were independently and significantly correlated with the risk for exacerbations of COPD. Conclusion: Low cFLC may be a B-cell-associated novel biomarker associated with risk of COPD exacerbation. | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | European Respiratory Society (ERS) | en |
dc.rights | © ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. | en |
dc.title | Low serum free light chain is associated with risk of COPD exacerbation | en |
dc.type | journal article | - |
dc.type.niitype | Journal Article | - |
dc.identifier.jtitle | ERJ Open Research | - |
dc.identifier.volume | 6 | - |
dc.identifier.issue | 2 | - |
dc.relation.doi | 10.1183/23120541.00288-2019 | - |
dc.textversion | publisher | - |
dc.identifier.artnum | 00288-2019 | - |
dc.identifier.pmid | 32665945 | - |
dcterms.accessRights | open access | - |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。